

# Protein 50S ribosomal subunit inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/PB7F65DD0828EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PB7F65DD0828EN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Protein 50S Ribosomal Subunit Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Protein 50S Ribosomal Subunit Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Protein 50S Ribosomal Subunit Inhibitors Understanding

#### Protein 50S Ribosomal Subunit Inhibitors: Overview

50S, roughly equivalent to the 60S ribosomal subunit in eukaryotic cells, is the larger subunit of the 70S ribosome of prokaryotes. The 50S subunit is primarily composed of proteins but also contains single-stranded RNA known as ribosomal RNA (rRNA). The bacterial ribosome is one of the main targets of antibiotics, with most clinically used antibiotics targeting peptidyl-transferase centre on the large subunit (50S subunit).

Function – 50S includes the activity that catalyzes peptide bond formation (peptidyl transfer reaction), prevents premature polypeptide hydrolysis, provides a binding site for

the G-protein factors (assists initiation, elongation, and termination), and helps protein folding after synthesis.

**Protein 50S Ribosomal Subunit Inhibitors-** The translational functions of the bacterial ribosome are the target for a large number of antimicrobial agents. There is a diverse range of clinically important antibiotics that interfere with protein synthesis by binding at various functional centers of the ribosome and either freezing a particular conformation of the ribosome or hindering the binding of its ligands.

### Protein 50S Ribosomal Subunit Inhibitors Emerging Drugs Chapters

This segment of the Protein 50S Ribosomal Subunit Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

### Protein 50S Ribosomal Subunit Inhibitors Emerging Drugs

#### Carrimycin: Shenyang Tonglian Group

Carrimycin is an antibiotic that also has anti-viral, anti-inflammatory and anti-fibrosis effects. It was originally developed in China by the Tonglian Group to treat community-acquired infections in adults caused by sensitive bacteria. The US Food and Drug Administration (FDA) has approved Phase III trials of a synthetic biological drug treatment for severe COVID-19, carrimycin.

Further product details are provided in the report.....

### Protein 50S Ribosomal Subunit Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Protein 50S Ribosomal Subunit Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players working on Protein 50S Ribosomal Subunit Inhibitors

There are approx. 3+ key companies which are developing the Protein 50S Ribosomal Subunit Inhibitors. The companies which have their Protein 50S Ribosomal Subunit Inhibitors drug candidates in the most advanced stage, i.e. preregistration include Biogen.

## Phases

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late-stage products (Phase III )

Mid-stage products (Phase II )

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Protein 50S Ribosomal Subunit Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intravenous

Intramuscular

Oral

Parenteral

Subcutaneous

## Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

## Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

## Protein 50S Ribosomal Subunit Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Protein 50S Ribosomal Subunit Inhibitors therapeutic drugs key players involved in developing key drugs.

## Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Protein 50S Ribosomal Subunit Inhibitors drugs.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Protein 50S Ribosomal Subunit Inhibitors R&D.

The therapies under development are focused on novel approaches for Protein 50S Ribosomal Subunit Inhibitors.

## Protein 50S Ribosomal Subunit Inhibitors Report Insights

Protein 50S Ribosomal Subunit Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Protein 50S Ribosomal Subunit Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Scenario and Emerging Therapies:

How many companies are developing Protein 50S Ribosomal Subunit Inhibitors drugs?

How many Protein 50S Ribosomal Subunit Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Protein 50S Ribosomal Subunit Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Protein 50S Ribosomal Subunit Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Protein 50S Ribosomal Subunit Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

## Contents

Introduction

Executive Summary

Protein 50S Ribosomal Subunit Inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Protein 50S Ribosomal Subunit Inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Protein 50S Ribosomal Subunit Inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends

Protein 50S Ribosomal Subunit Inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Carrimycin: Shenyang Tonglian Group

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Solithromycin: Melinta Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Protein 50S Ribosomal Subunit Inhibitors Key Companies

Protein 50S Ribosomal Subunit Inhibitors Key Products

Protein 50S Ribosomal Subunit Inhibitors- Unmet Needs

Protein 50S Ribosomal Subunit Inhibitors- Market Drivers and Barriers

Protein 50S Ribosomal Subunit Inhibitors- Future Perspectives and Conclusion

Protein 50S Ribosomal Subunit Inhibitors Analyst Views

Protein 50S Ribosomal Subunit Inhibitors Key Companies

Appendix



## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Protein 50S Ribosomal Subunit Inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Protein 50S Ribosomal Subunit Inhibitors

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Protein 50S ribosomal subunit inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/PB7F65DD0828EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB7F65DD0828EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970